GB0001646941/GBP/PLUS-exn
16 April 2010
EDEN RESEARCH PLC
("Eden" or "Company")
Submission of DAR for 3AEY by CRD
Eden Research plc, a leading UK agrochemical development company, today announces that it has been informed
by the Chemicals Regulation Directorate ("CRD") that the review of the Draft Assessment Report ("DAR") for
the Company's lead product, 3AEY, and its three active components, has been completed and submitted to the
European Foods Safety Authority ("EFSA"). The CRD has recommended that Eden undertakes an additional assay
study as some EU member states may require it for national approval and, in order to expedite sales of
Eden's product, this will be done in the next few months.
The submission of the DAR to EFSA triggers a milestone payment of £38,000 by one of Eden's licensees,
Environmental Solutions North Africa Limited, under the licensing agreement.
The completion of the review by CRD is a major step forward in the route to full commercialisation of 3AEY,
a terpene based fungicide. Terpenes are natural compounds which function as defence mechanisms in many
plant groups and are released in response to infection, stress or mechanical injury. Their natural disease
control has been acknowledged for some time, but it is Eden's unique patented encapsulation process of
3AEY, which allows the slow release of terpenes, that forms the revolutionary aspect of this treatment. The
specific application covered by the DAR is for the control of the fungal disease, botrytis, in grape vines.
Botrytis is a widespread fungal problem that causes "grey mould" on fruits and vegetables, often arising
late in the growing cycle and leading to the rapid reduction in marketable yield and lower quality of
crops. Annual worldwide expenditure on fungicides to control botrytis is typically c.$300m.
The announcement of this "green" development is especially important and timely as the new regulatory
controls on EU pesticides are expected to significantly reduce the already diminished arsenal of control
chemicals available to farmers and growers.
Once the DAR is received by EFSA, the process of gaining national registrations for sale can commence.
Prior to full EU approval, individual countries may issue 'provisional approval' for use. Such provisional
approval, subject to the territory, would allow sales of 3AEY to begin through Eden's existing EU
licensees. It will also benefit our current licensees in other territories, particularly in North Africa
(Environmental Solutions) and East Africa (Lachlan Kenya) where crops are being grown for export to the EU.
Clive Newitt, Managing Director of Eden Research, said:
"The submission of the DAR represents a major milestone in the approval process for our lead product, 3AEY.
This not only paves the way for the commercialisation of 3AEY, but also provides a very firm footing for
the registration of further products from our pipeline as they are based upon the same active substances in
different combinations and ratios.
Our products offer viable alternative methods of controlling damaging pests and diseases which can be fully
incorporated into Integrated Crop Management programmes and thereby minimise future resistance problems."
The directors of Eden Research plc are responsible for the contents of this announcement.
Enquiries:
Eden Research plc 01993 862761
Clive Newitt, Managing Director
St Helens Capital Partners LLP 020 7368 6959
Mark Anwyl
Threadneedle Communications 020 7653 9850
Josh Royston
Beth Harris
Eden Research plc
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.